This includes treatments such as anti‐programmed death protein‐1/ligand‐1 (aPD‐1/PD‐L1) therapy and chimeric antigen receptor T (CAR‐T) cell therapy.[3] However, only 20–30% of cancer patients respond favorably to aPD‐1/PD‐L1 therapies, primarily due to the scarcity of tumor antigen presentation and limited infiltrating cytotoxic T cells.[4] Moreover, CAR‐T cell treatment has shown limited success in managing solid tumors, particularly in TNBC patients.[5] Consequently, it is necessary to develop new strategies to enhance anticancer immune response. Here, CD274 is linked to neoplasm.